SCHEDULE: Armistice Capital Discloses 9.54% Stake in GeoVax

Armistice Capital, LLC and Steven Boyd have reported a 9.54% beneficial ownership stake in GeoVax Labs, Inc., holding 2,675,610 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 2,675,610 shares of GeoVax Labs, Inc. common stock.
• This ownership represents 9.54% of the total outstanding common stock of GeoVax Labs, Inc.
• The shares are held with shared voting power and shared dispositive power by the reporting persons.
• The filing is an Amendment No. 1 to a previously filed Schedule 13G, indicating an update to prior ownership disclosures.
• The event requiring this filing occurred on June 30, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by an institutional fund, which can be viewed as a vote of confidence, though it does not provide operational or financial performance details.

Positives

• A significant institutional investor, Armistice Capital, LLC, along with Steven Boyd, holds a substantial 9.54% stake in GeoVax Labs, Inc., which can be interpreted as a vote of confidence in the company's prospects.

Negatives

• No specific negative information regarding GeoVax Labs, Inc.'s operations, financial health, or strategic direction is disclosed in this beneficial ownership filing.

Future Outlook

This beneficial ownership filing does not provide any forward-looking statements or guidance regarding GeoVax Labs, Inc.'s future operations or financial performance.

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide specific industry context or analysis of broader industry trends.

Stakeholder Impact

• Shareholders: Increased institutional ownership (9.54%) by Armistice Capital, LLC and Steven Boyd may enhance market visibility and potentially liquidity for GeoVax Labs, Inc.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive stake by Armistice Capital, LLC and Steven Boyd in GeoVax Labs, Inc. While the filing itself does not provide operational or financial performance data, the presence of a notable institutional investor holding 9.54% of the common stock suggests a degree of confidence in the company. However, without further financial or strategic updates from GeoVax, a 'hold' recommendation is appropriate, as this filing alone does not provide sufficient grounds for a 'buy' or 'sell' decision.

Keywords

GeoVax Labs, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment